相关实验视频

Updated: Sep 15, 2025

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

作为抗神经退行的一种多目标剂的Equol:对其分子调制的机械洞察力

Nushrat Jahan¹, Lovedeep Singh², Jyoti Sharma³

¹University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.

Neuromolecular medicine

|July 16, 2025

概括

埃科尔是一种大豆代谢物,通过向神经退行性疾病中涉及的多个途径,包括氧化应激和炎症,显示出神经保护的前景. 这篇评论探讨了equol如何调节关键介导体来对抗神经元死亡.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

神经退行性疾病是渐进性的神经元疾病,其全球影响越来越大.
病理生理学涉及氧化应激,神经炎症,化应激和亡.
目前的治疗方法提供症状缓解,需要针对多种机制的新型治疗策略.

研究的目的:

审查通过equol赋予神经保护的机制性途径.
探索Equol作为神经退行性疾病治疗剂的潜力.
为了突出equol调节神经退行相关的关键分子标的能力.

主要方法:

关于equol和神经保护的研究的文献综述.
对equol对信号通路的调制进行分析 (例如,TLR-4/MAPK/NF-κB,NLRP3炎症体).
检查equol对氧化应激 (ROS),神经炎症和亡的影响.

主要成果:

埃科尔调节关键介质,包括TLR-4,MAPK,NLRP3炎症体,ROS和炎症介质.
通过向多个病理途径,Equol显示出神经保护作用.
降低雌激素受体表达会加剧神经退行,这是一个可能受到Eqol影响的因素.

结论:

在通过多目标调制来对抗神经退行症方面,Equol具有显著的潜力.
对equol在神经退行性疾病中的治疗应用进行进一步的研究是有必要的.
埃科尔代表了一种有前途的植物分子,用于解决神经退行症的复杂病理生理学.

关键词:

在Equol中使用Equol.雌激素受体是一种受体.在NLRP3中,NLRP3是NLRP3中的一个.氧化 (NOX) 是一种有机物.神经退行发生神经退行.这就是ROSOS ROS.在TLR-4/MAPK中使用.

更多相关视频

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Published on: September 27, 2020

相关概念视频

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...